Provention Bio, in need of AdComm's support for diabetes drug, may have what it needs to satisfy the FDA

Provention Bio, in need of AdComm's support for diabetes drug, may have what it needs to satisfy the FDA

Source: 
Fierce Biotech
snippet: 

Provention Bio’s stock flew skyward Tuesday as FDA advisory panel documents apparently backed the efficacy of its diabetes prevention drug teplizumab while avoiding a larger question about the quality of the biotech's manufacturing.